

# REVISTA INTERNACIONAL DE ANDROLOGÍA. SALUD SEXUAL Y REPRODUCTIVA

## INSTRUCTIONS FOR AUTHORS

*Updated 2015*

### GENERAL INFORMATION

*Revista Internacional de Andrología. Salud sexual y reproductiva* ([www.elsevier.es/andrologia](http://www.elsevier.es/andrologia)) is a tri-monthly journal that will consider for publication manuscripts in Spanish or Portuguese related to any area of andrology and sexual and reproductive health.

The journal is included in Science Citation Index Expanded, Journal of Citation Reports, EMBASE, Scopus, Science Direct and publishes original articles, case reports, review articles, special articles and letters to the editor. All manuscripts undergo peer review by external anonymous referees.

Manuscripts should comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals of the International Committee of Medical Journal Editors, available at <http://www.icmje.org>, adapted to the following instructions.

### MANUSCRIPT SUBMISSION

Manuscripts should be sent by electronic mail through the Elsevier editorial system (EES) on the journal's website <http://ees.elsevier.com/androl>, which contains all the information required for submission. Authors can track the status of their manuscripts through this webpage. A cover letter (see below) should also be entered in the EES's **Enter Comments** section.

The body of the manuscript (except the first, or title page), the abstract in English and Spanish, key words in English and Spanish, references, tables, table and figure legends should be included in a single file. Include each figure in a separate file. These documents should be uploaded in the **Attach Files** section.

Consult the general instructions for use of the EES in the tutorial for authors:

<http://epsupport.elsevier.com/al/12/1/article.aspx?aid=1562&bt=4>

## SECTIONS

**Original articles.** These articles include empirical studies on any aspect of research in the field of andrology, sexuality or reproduction structured under the following sections: introduction, methods, results and discussion. The maximum length is 11 ISO-A4 pages, including a structured abstract of no more than 250 words, key words and up to 35 references. Up to 4 figures or tables will be accepted. The number of authors should not exceed 6.

Authors preparing randomized controlled clinical trials are advised to consult the CONSORT statement (JAMA.1996;276:637-9) available at: <http://www.consort-statement.org/>. Authors preparing metaanalyses should consult the QUOROM statement (<http://www.consort-statement.org/QUOROM.pdf>). Manuscripts reporting the results of studies evaluating diagnostic accuracy should include the STARD flow diagram (<http://www.consort-statement.org/stardstatement.htm>).

**Case reports.** This section publishes cases making a substantial contribution to knowledge of the physiopathology, etiology or other aspects of a clinical process. The maximum length is 1,500 words, or 5 ISO-A4 sheets, including an unstructured abstract of 150 words and up to 15 references. These studies should follow the same structure as original articles (introduction, methods, results and discussion) and up to 3 tables and/or figures will be accepted. There should be no more than 4 authors.

**Review articles.** These articles are solicited by the Editorial Board. Authors interested in publishing an article in this section may contact the journal's editors. These manuscripts discuss topics of current importance in andrology. The maximum length is 16 ISO-A4 sheets, including an abstract in English and Spanish of 150 words for unstructured abstracts (or 250 words for structured abstracts) and key words in Spanish and English. Up to 50 references and up to 4 figures or tables will be accepted. There should be no more than 3 authors. Review articles should include an unstructured abstract of 300 words and up to 100 references.

**Opinion articles.** This section publishes manuscripts on subjects of current importance in andrology that contain novel perspectives for the specialty. The text need not be structured in a particular format but should be logically developed (introduction, development, conclusions). The maximum length is 10 ISO-A4 pages including an abstract in

English and Spanish of 150 words for unstructured abstracts (or 250 words for structured abstracts) and key words in Spanish and English. Up to 15 references and up to 2 figures or tables will be accepted.

**Letters to the editor.** This section includes observations or opinions related to articles recently published in the journal and experiences that can be summarized in a short text. The maximum length is 2 ISO-A4 sheets, with no abstract, and up to 5 references. The number of authors should not exceed 4. Up to 1 figure or 1 table will be accepted.

**Other sections.** The journal publishes other sections (Editorials, Special articles, among others). Articles published in these sections are solicited by the Editorial Board. Authors interested in publishing in one of these sections should previously contact the journal's associate editors.

## COVER LETTER

All manuscripts should be submitted with a cover letter (please see the section on "Author's obligations"), which should be uploaded in the **Attach Files** section of the EES which, in addition to the title of the manuscript, should contain the following:

- 1) the section of the journal in which publication is sought;
- 2) a statement that the work is an original study and is not being evaluated by any other scientific journal;
- 3) an explanation, in a maximum of one paragraph, of the manuscript's original contribution and importance in the field covered by the journal;
- 4) a statement that the authors have prepared the manuscript bearing in mind the "Ethical responsibilities" included in these instructions, and, among these: a) that the procedures performed were in accordance with the ethical standards of the responsible committee on human or animal experimentation (institutional or regional) and with the World Medical Association and the Declaration of Helsinki; b) that patients' privacy and confidentiality are guaranteed, in line with the corresponding section of these instructions and that the manuscript contains no data or images that could identify patients; and c) that all patients signed informed consent forms to participate in the study and agree to publication of the results on the internet as an open-access article in *Revista Internacional de Andrología. Salud sexual y reproductiva* and that compliance with these requirements has been stated in the EES;
- 5) disclosure of any grant (technical or financial) from an institution;
- 6) confirmation that signed authors meet the requirements for authorship (a description of each author's contribution is optional) in agreement with the requirements in the *Authorship* section of these instructions and with the statement in the EES;
- 7) if any part of the manuscript has been previously published in another journal (*redundant or duplicate*

*publication*), authors must provide details in the cover letter and state that the relevant permissions have been obtained from the author of the article and the editor of the journal in which it was published (see also the section on "*Warranties and copyright transfer*");

- 8) a statement by each of the authors of the existence or absence of any conflict of interests and confirmation that this statement has been made in the EES' **Additional Information** section.

Authors may propose suitably qualified persons to act as referees. Persons who have collaborated or been coauthors in studies performed in the last three years or who have made a substantial critical review of the manuscript cannot be designated as referees. Suggestions on reviewers can be made in the **Suggest Reviewers** section of the EES.

## MANUSCRIPT PRESENTATION

Manuscripts may be written in Spanish or Portuguese and typed double-spaced in 11-pitch font on ISO-A4 sheets. Pages must be numbered consecutively.

Define all abbreviations on first mention in the text, except in the title. SI units are preferred. Use a comma as a decimal separator and a period for large figures.

### 1. Title page

The title page should contain the following information:

- The title of the manuscript (in Spanish or Portuguese and in English for the abstract). The title should accurately reflect the article's content. Be brief, clear and informative. Do not use abbreviations.
- Authors' first name and second name(s) (if two second names are used, they should be joined by a hyphen). Authors are recommended to use their "bibliographical signature" by using only one second name joined by a hyphen to avoid confusion in bibliographical databases.
- The name of the department(s) and institutions(s) where the work was performed. Do not include professional or academic positions.
- The complete name, telephone number, e-mail and postal addresses of the corresponding author, who will be responsible for correcting the proofs.

The first page should be submitted in a separate file from the rest of the manuscript.

### 2. Abstract and key words (2nd page)

The abstract should be written in Spanish or Portuguese. Provide an unstructured abstract of 150 words for "Reviews" and "Brief reviews". For "Original articles" provide a 250-word abstract structured under the following headings: *Objective*: state the main aim of the study; *Material and method*: state the study's design, the evaluation criteria for diagnostic tests and whether the study was retrospective or prospective. Mention the procedure used for patient selection, inclusion criteria and the number of patients who started and finished the study; *Results*: state the most

important results as well as their statistical significance; *Conclusions*: provide conclusions that are directly supported by the results and their clinical applications. Emphasis to positive and negative results with similar scientific interest equally.

Provide 3-8 key words at the end of the abstract included in the Medical Subject Headings (MeSH) of Index Medicus/MEDLINE, available in English at: <http://www.nlm.nih.gov/mesh/meshhome.html> and translate them to Spanish.

After the abstract and key words in Spanish, provide a complete and faithful translation of the title, abstract and key words to English.

### 3. Main text (3rd and subsequent pages)

- a) *Introduction*. Summarize the background of the study, without exhaustively reviewing the topic, and conclude with a clear statement of the study's aims. Cite only the references that are strictly necessary following the criteria of topicality and relevance to the study's aims.
- b) *Material and methods*. Specify the place and period or duration of the study, patient characteristics, the selection criteria and techniques used and accurately describe how the study was performed, the study's design, procedures, inclusion and exclusion criteria, treatment regimens, statistical analysis, etc. This section should include sufficient information for other authors to reproduce the work. When applicable, briefly describe the ethical guidelines followed by the researchers, both in observational and in experimental or quasi-experimental studies. Manuscripts reporting studies in humans should state that the study was expressly approved by the corresponding ethics committee (see "Ethical requirements" below). The study design should be concisely described. Statistical methods not routinely used in andrology research should be described in sufficient detail.
- c) The results should be clear and concise and include the minimum number of tables and figures necessary, depending on the type of study. Do not repeat information in the text and in the tables and figures.
- d) *Discussion*. Authors should present their own opinions on the subject. Emphasize the following: a) the significance and practical applications of the results; b) any possible inconsistency in the methodology, the reasons why the results may be valid and their limitations and relate them to the results of other important studies; c) comparison of the results with those of similar publications and areas of agreement and disagreement, and d) recommendations for future research. The discussion should not provide a review of the topic and should not repeat concepts mentioned in the introduction or data from the results section. Discuss the results of the study in relation to those of previous studies, as well as similarities and differences and their interpretation. This section should end with a paragraph providing a conclusion.

### 4. Information added by the journal

At this point, the publisher will add the information on "Author's obligations" declared in the EES relating to

"*Ethical responsibilities*" specifically that relating to: a) protection of persons and animals; b) confidentiality, and c) the right to privacy and informed consent; funding; authors' contributions (optional); and the declaration of each of the authors on the presence or absence of conflicts of interest.

### 5. Acknowledgments

Only acknowledge persons who have clearly contributed to making the article possible but who are not cited as authors. All persons specifically mentioned in this section should approve of their inclusion. Acknowledge technical support in a different paragraph from those acknowledging financial and material aid from institutions, which should be included under "Funding" and could lead to a potential conflict of interests.

### 6. References

Number references consecutively in superscript Arabic numerals in the order of their first appearance in the text, tables and figures. Numbers should be placed before punctuation marks (for example: "...unlike previous studies", the results show.."). Personal communications and unpublished data that are not "in press" should not be included in the references section but may be cited in parentheses in the text.

Abbreviate journal names according to the style used by *Index Medicus* of the US National Library of Medicine, available at: [www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=journals](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=journals).

References must be checked against the original documents. When indicating the first and last page numbers, use only the digits differing from those of the first page (for example: 34-9, not 34-39; 136-41, not 136-141). The accuracy of references is of the utmost importance and should be guaranteed by authors. References should be formatted according to the Vancouver style. Examples of the formats used for distinct types of article are provided below (for formats not included in this list, please consult further examples at <http://www.icmje.org>).

#### Journal Article

Include authors' second name and initials, separated by comas. Cite all authors if there are 6 or less, with a comma between each name and a period after the last author; if there are 7 or more authors, cite the first 6 and add the expression et al. Then provide the title of the article in the original language, followed by a period, the abbreviated title of the journal, also followed by a period, year of publication, followed by a semi-colon, volume number, followed by a colon, and the first and last pages, separated by a hyphen.

#### Standard journal article with less than 6 authors

Armendáriz-Rubio P, De Miguel Velasco M, Ortiz Hurtado H. Comparación de colostomías e ileostomías como estomas derivativos tras resección anterior baja. *Cir Esp*. 2007;81: 115-20.

#### *Standard journal article with more than 6 authors*

Bujalance Cabrera FM, Herrera Merino N, Salvador Fernández M, Escudero Escudero J, Sierra Ortega MA, Oliva Díaz C, et al. Tratamiento quirúrgico de la peritonitis. *Cir Esp.* 2007;81:139-43.

#### *Journal supplement*

Del Río C, Biondo S, Martí-Ragué J. Incontinencia fecal. Valoración del paciente. Tratamientos clásicos. *Cir Esp.* 2005;78 Suppl 3:34-40.

#### *Article in press*

Serra C, Baltasar A, Pérez N, Bou R, Bengochea M. Regastrectomía tubular laparoscópica. *Cir Esp.* In press 2007.

#### *Organization as author*

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension.* 2002;40:679-86.

#### *Both individual and organization as authors*

Vallancien G, Emberton M, Harving N, Van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. *J Urol.* 2003;169:2257-61.

#### *No author*

21st century heart solution may have a sting in the tail. *BMJ.* 2002;325:184.

#### *Volume with supplement*

Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache.* 2002;42 Suppl 2:S93-9.

#### *Issue with supplement*

Glauser TA. Integrating clinical trial data into clinical practice. *Neurology.* 2002;58(12 Suppl 7):S6-12.

#### **Book**

##### *Editors as authors*

Mvoelkel NF, MacNee W, editors. *Chronic obstructive lung diseases.* Hamilton: BC Decker Inc.; 2002.

##### *Personal author(s) (not editors)*

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology.* 4<sup>th</sup> ed. St. Louis: Mosby; 2002.

##### *Distinct authors and editors*

Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. In: Wieczorek RR, editor. *White Plains: March of Dimes Education Services;* 2001.

##### *Organization as author*

Royal Adelaide Hospital; University of Adelaide, Department of Clinical Nursing. *Compendium of nursing research and practice development, 1999-2000.* Adelaide: Adelaide University; 2001.

#### *Chapter in a book*

Weibel ER. The structural basis of lung function. In: West JB, editor. *Respiratory physiology: people and ideas.* New York: Oxford University Press; 1996. p. 3-46.

#### **Documents in electronic format**

##### *Standard article in electronic format*

Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis.* [online journal] 1995;1 [consulted 05-06-1996]: Available at: <http://www.cdc.gov/ncidod/EID/eid.htm>

##### *CD-ROM*

Anderson SC, Poulsen KB. Anderson's electronic atlas of haematology [CD-ROM]. Philadelphia: Lippincott Williams & Wilkins; 2002.

##### *Internet page*

Cancer-Pain.org [Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 16th May 2002; cited 9th July 2002]. Available at: <http://www.cancerpain.org/>

#### **Other published material**

##### *Conference proceedings*

Harnden P, Joffe JK, Jones WG, editors. *Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference;* 13-15 September 2001; Leeds, UK. New York: Springer; 2002.

## **7. Tables**

Submit tables on separate sheets and include: a) the table number in Arabic numerals; b) the title of the table, and c) a single table per sheet. Tables should be presented as clearly as possible and should be understood by readers without reference to the text; define all abbreviations and symbols in a footnote. If a table requires two pages, repeat the headings on the second page. The journal will accept tables that occupy up to one printed page. State statistical significance in a footnote, if not included in the table itself.

## **8. Figure legends**

Type figures double-spaced on separate sheets. Legends and footnotes should contain sufficient information for the data to be understood without reference to the text. Clearly explain any symbols, arrows, numbers or letters used to illustrate part of the figure in the legend with an explanatory footnote using superscript letters in alphabetical order (<sup>a</sup>, <sup>b</sup>, .....). Histological reproductions should specify the magnification ratio and staining method. There is a charge for publishing color photographs and authors wishing to do so should previously request a budget from ELSEVIER ESPAÑA, SL, expressly stating that they wish their photographs to be published in color.

Send figures in a separate file from the text, preferably in JPG or TIFF format and with a resolution of 300 dots per inch (dpi). All graphs, drawings and photographs are considered figures. Authors will be charged for publishing photographs in color and those wishing to do so should

previously request a budget from the journal. Number figures with Arabic numerals according to their order of appearance in the text.

After informing authors, the Editorial Board reserves the right to reject figures not deemed to be of sufficient quality to ensure good reproduction. Graphs and drawings will be reproduced in 9 x 12 cm or multiples thereof. The same considerations apply as for photographs.

Clearly explain any symbols, arrows, numbers of letters used to indicate one or several parts of the figure in a footnote.

Images or data must not allow study subjects to be identified. Authors must have obtained written informed consent from patients authorizing publication, reproduction and dissemination in both the printed and electronic forms of the journal.

Authors are responsible for obtaining permission for reproduction of material (text, tables or figures) from other publications. Such permission must be sought both from the author and from the publisher of the material.

## AUTHORS' OBLIGATIONS

### 1. Ethical responsibilities

**Protection of persons and animals.** When reporting experiments in human subjects, indicate whether the procedures performed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the World Medical Association and Helsinki Declaration, available at: <http://www.wma.net/en/30publications/10policies/b3/>. When describing experiments in animals, indicate whether the procedures were in accordance with the standards of an institution or an international research council or a national law regulating the handling and use of laboratory animals.

**Confidentiality.** Authors are responsible for following the protocols established by their corresponding centers for access to medical histories for research, publication and dissemination purposes and must state their compliance with these protocols. Authors must warrant that all patients included in the study were suitably informed and signed an informed consent form to participate in the study. Authors must state in the Methods section that the procedures used in patients and control subjects were performed after *informed consent* was obtained.

**Privacy.** Authors are responsible for protecting patients' right to privacy by masking their identity both in the text and in photographs. Do not use patients' names, initials, or medical records numbers (or any other data irrelevant to the research that could identify patients) or in the text or photographs, unless such information is essential for scientific reasons, in which case, this information can be used as long as the patient - or his/her parent or guardian - provides written informed consent for publication. Authors are responsible for obtaining written consent, authorizing publication, reproduction and dissemination

of such material in print and as an open-access article on the Internet.

### 2. Funding

Authors must disclose any financial aid received. Authors should state whether the research was funded by the US National Institutes of Health or whether any of the authors belongs to the Howard Hughes Medical Institute.

### 3. Authorship

Only persons who have made a substantial intellectual contribution to the study should be listed as authors. Participation in data collection or technical procedures does not by itself justify authorship. Authors should have made a sufficiently substantial contribution to the design and performance of an article to be able to accept responsibility for its contents and should also approve of the final version of the manuscript. In general, to be credited as an author, individuals should have:

1. participated in the conception and performance, data acquisition, and analysis and data of the work that has resulted in the submitted manuscript.
2. participated in the drafting of the article and in its possible revisions.
3. approved the final version to be published.

In the case of collective authorship, cite the authors who drafted the manuscript or those responsible for the study followed by "and the .... Group" when all members of the group are considered coauthors. If the name of the group is included, although not all its members are considered coauthors, mention the authors responsible for the study followed by "on behalf of the .... Group" or "for the .... Group". In either case, include the names and institutions of the group in an appendix at the end of the manuscript.

Authors should be named both on the title page of the manuscript and in the ADD/EDIT/REMOVE AUTHOR section.

*Revista Internacional de Andrología. Salud sexual y reproductiva* will not accept responsibility for any possible conflicts derived from the authorship of manuscripts published in the journal.

### 4. Conflict of interests

A conflict of interest is considered to exist when authors have or have had financial or personal relations that could bias or inappropriately influence their actions. Potential conflicts of interest exist independently of whether the interested parties consider that their relationship influence their scientific criteria or not.

Authors must disclose in the COVER LETTER and in the ADDITIONAL INFORMATION section of the EES any financial or personal relationship they have or have had when writing the article with persons or institutions that could have given rise to a conflict of interest with regard to the manuscript submitted for publication. The declaration of conflict of interest will be published in the printed journal (see also the *Acknowledgments* section).

## 5. Permissions

Authors are responsible for obtaining permission to partially reproduce material (text, tables or figures) from other published works. These permissions should be requested from both the author and the publisher of the work. Permission to publish the work from the institution funding the research is required.

Authors must declare that the manuscript contains original work, has not been previously published and is not under evaluation by any other publication, either in its entirety or in part. Authors must be aware that failure to disclose that the material submitted for publication has been previously published, whether in its entirety or in part, constitutes a serious breach of scientific ethics. Authors are responsible for obtaining permission to reproduce material (text, tables or figures) from previously published works. Written permission must be requested from both the author and the publisher of the work and copies of these permissions must be included along with the manuscript.

## 6. Redundant or duplicate publication

The journal will not accept previously published material and will not consider for publication manuscripts simultaneously submitted to other journals, or redundant or duplicate publications, i.e. articles that substantially overlap with another publication, when printed or in electronic format. Authors must mention in the cover letter any submissions or prior publications of the same work, in whole or in part, that could be considered redundant or duplicate publication. Reference(s) to prior publication(s) must be cited in the new manuscript. These restrictions do not apply to published abstracts of communications presented at national or international congresses.

## EDITORIAL PROCESS

Authors can track their manuscript's status through the EES using the registration number they will receive together with an acknowledgement of receipt.

The Editorial Board will make an initial evaluation of the manuscript within 3 weeks of its receipt. All manuscripts receiving a favorable initial review will be sent to external referees, usually two. Peer reviewers are anonymous. Manuscript review usually takes approximately 2 months, after which time the corresponding author will be informed of the decision (accepted without changes, minor revision, major revision, rejection) and the steps the authors must take for the manuscript to be finally accepted (for manuscripts not rejected).

Whenever the Editorial Board requests changes to be made to a manuscript, the authors should submit the revised version through the EES within 15 natural days, together with a letter, entered in the **Respond to Reviewers** section of the EES, providing a detailed explanation of the changes made, both those suggested by the Editorial Board and those indicated by the reviewers. If the 15-day deadline is exceeded, the corresponding author will be informed that the manuscript has been withdrawn from the system.

Manuscripts will not be definitively accepted until satisfactory responses have been made to all suggestions.

The Editorial Board reserves the right to reject articles not deemed appropriate, as well as to edit the style and/or shorten the text of manuscripts requiring such changes but without modifying the manuscript's original content. The author will receive a message through the EES requesting his/her approval of the final version.

All articles submitted to the journal will be anonymously reviewed by expert, independent peer-reviewers. To ensure that peer review is blind, authors' names and those of the institutions or centers where the work was performed should appear on the title page only. Exceptionally, Letters to the Editor may be accepted by the Editorial Board without peer review.

The corresponding authors of accepted manuscripts will receive page proofs of the article, which should be corrected and returned within 48 hours. The Editorial Board will take no responsibility for any errors or omissions that may be published in manuscripts not returned within this deadline. Only minimal corrections should be made at this stage (errata). The Editorial Board reserves the right to accept or reject the changes made by authors in the proofs.

The following paragraphs reproduce the text on author's warranty and copyright transfer:

## COPYRIGHT TRANSFER

**1. Author's warranty and copyright transfer.** Submission through this medium of a text, including any graphics, designs or illustrations (hereinafter referred to as "the Work") presupposes acceptance of the following conditions:

The author warrants that the Work submitted to Elsevier España, S.L., for publication in this journal or in any other products derived from this journal is an original Work, has not been previously published and has not been submitted simultaneously for publication elsewhere, and was written by the author.

The author warrants, under his/her responsibility, that he/she is the sole and exclusive owner of the copyright of the Work, that the Work does not infringe on third party copyright material, that he/she has obtained permission notices from the copyright owners where required, and that he/she authorizes their exploitation by Elsevier España, S.L..

The author warrants that the Work submitted to Elsevier España, S.L. does not infringe personal data protection legislation. In particular, the author warrants that he/she has obtained prior written authorization and consent from patients or their families for publication of the Work when these patients are identified in the Work or when the published information could make them easily identifiable.

**2. Transfer of exploitation rights.** The author assigns to the Spanish Association of Andrology. Sexual and Reproductive Medicine exclusively and with powers of release to third parties, the worldwide rights to any Works accepted for publication in this journal, as well as those to any

products resulting from these Works, and in particular the rights to reproduction, distribution, public communication (including interactive communications) and transformation (including adaptation, modification and translation) in all exploitation media (including without limitation: print, electronic, on-line, informatic or audiovisual support as well as any other format, including for advertising or promotional purposes and/or for related products) for the full period of the Revised Law of Intellectual Property currently in force.

Consequently, the author may not publish or disseminate any Works selected for publication in *Revista Internacional de Andrología. Salud sexual y reproductiva*, either partially

or in full, nor may he/she authorize their publication to third parties without the express prior written permission of Spanish Association of Andrology. Sexual and Reproductive Medicine.

## **EDITORIAL POLICY**

The judgments and opinions expressed in the articles and communications published in the journal are exclusively those of the author(s). Neither the Editorial Board nor Elsevier España S.L., will accept any responsibility for the material published.